Levobupivacaine to the Surgical Wound Following Cesarean
Primary Purpose
Postoperative Pain
Status
Completed
Phase
Phase 3
Locations
Spain
Study Type
Interventional
Intervention
Levobupivacaine
NaCl
Sponsored by
About this trial
This is an interventional treatment trial for Postoperative Pain focused on measuring cesarean section, wound infusion, Local anesthetic levobupivacaine, Pain management
Eligibility Criteria
Inclusion Criteria:
- Full-term pregnant women who undergo scheduled cesarean surgery under intradural anesthesia.
- Duly informed patients who have signed the informed consent during the preanesthesia consultation, or after a period of consideration if necessary, expressing their consent to be included in the study.
- Between 18-45 years of age.
- ASA I and II.
- Sufficient intellectual ability to understand the technique as well as the equipment being used.
Exclusion Criteria:
- Failure to meet any of the above criteria.
- Presence of a major medical, cardiovascular, pulmonary, metabolic, renal or liver disorder.
- Preeclampsia and/or HELLP syndrome.
- Coagulopathy
- Profuse bleeding greater than 1000 ml or that which provokes hemodynamic instability that requires aggressive fluid therapy and/or transfusion.
- Allergy to any drug included in the protocol.
- Psychiatric or neurological pathology.
- Preexisting infection.
- Previous treatment with opioids or antidepressants or suffer from chronic pain.
- History of alcohol or drug abuse or known consumption of medications that interfere with LB metabolism.
Sites / Locations
- Teresa Herrera Hospital; A Coruña University Hospital Complex
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Levobupivacaine
NaCl
Arm Description
Continuous levobupivacaine subfascial infusion
Continuous NaCl subfascial infusion
Outcomes
Primary Outcome Measures
Area of incisional secondary hyperalgesia
Secondary Outcome Measures
Pain relief
consumption of morphine (mg) and paracetamol (gr)
Incidence of chronic pain
Pharmacokinetic variables of levobupivacaine
Cmax, Area Under Curve, Tmax
Incidence of complications and/or side effects related to the technique
Rate of satisfaction experienced by the patients through a survey
endocrin-metabolic response
Full Information
NCT ID
NCT01458431
First Posted
October 17, 2011
Last Updated
December 20, 2014
Sponsor
Manuel Ángel Gómez-Ríos
1. Study Identification
Unique Protocol Identification Number
NCT01458431
Brief Title
Levobupivacaine to the Surgical Wound Following Cesarean
Official Title
Efficacy of Continuous Infusion of Levobupivacaine to the Surgical Wound Following Cesarean
Study Type
Interventional
2. Study Status
Record Verification Date
October 2011
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
September 2014 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Manuel Ángel Gómez-Ríos
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The postoperative period following cesarean is associated with moderate to severe pain that requires a considerable amount of analgesics that carry with them side-effects such as nausea, vomiting, fatigue and immobilization. Several studies have tried, with variable results, to find a more effective analgesia alternative such as infusion of local anesthetics through a catheter in the surgical wound sinus, a practice that has currently been widely used in clinical practice. Despite existing references on its use in the postoperative period following cesareans there continues to be a lack of information on other aspects. The investigators study hypothesis is that the use of levobupivacaine in the surgical wound will reduce the surface of hyperalgesia compared to the control group.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Postoperative Pain
Keywords
cesarean section, wound infusion, Local anesthetic levobupivacaine, Pain management
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
70 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Levobupivacaine
Arm Type
Experimental
Arm Description
Continuous levobupivacaine subfascial infusion
Arm Title
NaCl
Arm Type
Placebo Comparator
Arm Description
Continuous NaCl subfascial infusion
Intervention Type
Drug
Intervention Name(s)
Levobupivacaine
Other Intervention Name(s)
local anesthetic
Intervention Description
continuous levobupivacaine subfascial infusion
Intervention Type
Drug
Intervention Name(s)
NaCl
Other Intervention Name(s)
Placebo
Intervention Description
continuous NaCl subfascial infusion
Primary Outcome Measure Information:
Title
Area of incisional secondary hyperalgesia
Time Frame
72 hours
Secondary Outcome Measure Information:
Title
Pain relief
Time Frame
72 hours
Title
consumption of morphine (mg) and paracetamol (gr)
Time Frame
48 hours
Title
Incidence of chronic pain
Time Frame
6 month
Title
Pharmacokinetic variables of levobupivacaine
Description
Cmax, Area Under Curve, Tmax
Time Frame
72 hours
Title
Incidence of complications and/or side effects related to the technique
Time Frame
72 hours
Title
Rate of satisfaction experienced by the patients through a survey
Time Frame
72 hours
Title
endocrin-metabolic response
Time Frame
72 hours
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Full-term pregnant women who undergo scheduled cesarean surgery under intradural anesthesia.
Duly informed patients who have signed the informed consent during the preanesthesia consultation, or after a period of consideration if necessary, expressing their consent to be included in the study.
Between 18-45 years of age.
ASA I and II.
Sufficient intellectual ability to understand the technique as well as the equipment being used.
Exclusion Criteria:
Failure to meet any of the above criteria.
Presence of a major medical, cardiovascular, pulmonary, metabolic, renal or liver disorder.
Preeclampsia and/or HELLP syndrome.
Coagulopathy
Profuse bleeding greater than 1000 ml or that which provokes hemodynamic instability that requires aggressive fluid therapy and/or transfusion.
Allergy to any drug included in the protocol.
Psychiatric or neurological pathology.
Preexisting infection.
Previous treatment with opioids or antidepressants or suffer from chronic pain.
History of alcohol or drug abuse or known consumption of medications that interfere with LB metabolism.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manuel Á gómez-Ríos, MD
Organizational Affiliation
C.H.U. A Coruña
Official's Role
Principal Investigator
Facility Information:
Facility Name
Teresa Herrera Hospital; A Coruña University Hospital Complex
City
A Coruña
ZIP/Postal Code
15008
Country
Spain
12. IPD Sharing Statement
Citations:
PubMed Identifier
9861124
Citation
Moiniche S, Mikkelsen S, Wetterslev J, Dahl JB. A qualitative systematic review of incisional local anaesthesia for postoperative pain relief after abdominal operations. Br J Anaesth. 1998 Sep;81(3):377-83. doi: 10.1093/bja/81.3.377.
Results Reference
background
PubMed Identifier
8717568
Citation
Mecklem DW, Humphrey MD, Hicks RW. Efficacy of bupivacaine delivered by wound catheter for post-Caesarean section analgesia. Aust N Z J Obstet Gynaecol. 1995 Nov;35(4):416-21. doi: 10.1111/j.1479-828x.1995.tb02156.x.
Results Reference
background
PubMed Identifier
17116561
Citation
Liu SS, Richman JM, Thirlby RC, Wu CL. Efficacy of continuous wound catheters delivering local anesthetic for postoperative analgesia: a quantitative and qualitative systematic review of randomized controlled trials. J Am Coll Surg. 2006 Dec;203(6):914-32. doi: 10.1016/j.jamcollsurg.2006.08.007. Epub 2006 Oct 25. No abstract available.
Results Reference
background
PubMed Identifier
17525598
Citation
Lavand'homme PM, Roelants F, Waterloos H, De Kock MF. Postoperative analgesic effects of continuous wound infiltration with diclofenac after elective cesarean delivery. Anesthesiology. 2007 Jun;106(6):1220-5. doi: 10.1097/01.anes.0000267606.17387.1d.
Results Reference
background
PubMed Identifier
16798442
Citation
Ranta PO, Ala-Kokko TI, Kukkonen JE, Ohtonen PP, Raudaskoski TH, Reponen PK, Rawal N. Incisional and epidural analgesia after caesarean delivery: a prospective, placebo-controlled, randomised clinical study. Int J Obstet Anesth. 2006 Jul;15(3):189-94. doi: 10.1016/j.ijoa.2006.02.003.
Results Reference
background
PubMed Identifier
16980157
Citation
Zohar E, Shapiro A, Eidinov A, Fishman A, Fredman B. Postcesarean analgesia: the efficacy of bupivacaine wound instillation with and without supplemental diclofenac. J Clin Anesth. 2006 Sep;18(6):415-21. doi: 10.1016/j.jclinane.2006.01.001.
Results Reference
background
PubMed Identifier
12477585
Citation
Zohar E, Luban I, Zunser I, Shapiro A, Jedeikin R, Fredman B. Patient-controlled bupivacaine wound instillation following cesarean section: the lack of efficacy of adjuvant ketamine. J Clin Anesth. 2002 Nov;14(7):505-11. doi: 10.1016/s0952-8180(02)00422-1.
Results Reference
background
PubMed Identifier
20460027
Citation
Bamigboye AA, Hofmeyr GJ. Caesarean section wound infiltration with local anaesthesia for postoperative pain relief - any benefit? S Afr Med J. 2010 May 4;100(5):313-9. doi: 10.7196/samj.3716.
Results Reference
background
PubMed Identifier
19588413
Citation
Bamigboye AA, Hofmeyr GJ. Local anaesthetic wound infiltration and abdominal nerves block during caesarean section for postoperative pain relief. Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006954. doi: 10.1002/14651858.CD006954.pub2.
Results Reference
background
PubMed Identifier
8140877
Citation
Dahl JB, Moiniche S, Kehlet H. Wound infiltration with local anaesthetics for postoperative pain relief. Acta Anaesthesiol Scand. 1994 Jan;38(1):7-14. doi: 10.1111/j.1399-6576.1994.tb03830.x. No abstract available.
Results Reference
background
PubMed Identifier
35086112
Citation
Gomez-Rios MA, Codesido-Barreiro P, Seco-Vilarino C, Calvin-Lamas M, Curt-Nuno F, Nieto-Serradilla L, Rabunal-Alvarez MT, Fernandez-Rodriguez F, Peteiro-Cartelle J, Pensado-Boo R, Bou G, Pensado-Castineiras A, Casans-Frances R. Wound Infusion of 0.35% Levobupivacaine Reduces Mechanical Secondary Hyperalgesia and Opioid Consumption After Cesarean Delivery: A Prospective, Randomized, Triple-Blind, Placebo-Controlled Trial. Anesth Analg. 2022 Apr 1;134(4):791-801. doi: 10.1213/ANE.0000000000005917.
Results Reference
derived
Learn more about this trial
Levobupivacaine to the Surgical Wound Following Cesarean
We'll reach out to this number within 24 hrs